TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 OVERVIEW 16 1.1.1 MARKET SYNOPSIS 16 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 17 2.2 RESEARCH OBJECTIVE 17 2.3 LIST OF ASSUMPTIONS 17 3 RESEARCH METHODOLOGY 3.1 OVERVIEW 19 3.2 DATA MINING 19 3.3 SECONDARY RESEARCH 20 3.4 PRIMARY RESEARCH 21 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 21 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 22 3.5 FORECASTING TECHNIQUES 22 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 23 3.6.1 BOTTOM-UP APPROACH 24 3.6.2 TOP-DOWN APPROACH 25 3.7 DATA TRIANGULATION 25 3.8 VALIDATION 25 4 MARKET DYNAMICS 4.1 OVERVIEW 26 4.2 DRIVERS 27 4.2.1 RISING ADOPTION RATE OF INTERNET AND HEALTHCARE APPS 27 4.2.2 RISING OCCURRENCE OF CHRONIC AND INFECTIOUS DISEASES 27 4.2.3 INCREASING GERIARTIC POPULATION 27 4.3 RESTRAINTS 28 4.3.1 COUNTERFEIT MEDICINES 28 4.4 OPPORTUNITIES 29 4.4.1 NEED FOR EPHARMACY SERVICES IN EMERGING ECONOMIES 29 5 MARKET FACTOR ANALYSIS 5.1 PORTER’S FIVE FORCES MODEL 30 5.1.1 THREAT OF NEW ENTRANTS 30 5.1.2 BARGAINING POWER OF SUPPLIERS 31 5.1.3 THREAT OF SUBSTITUTES 31 5.1.4 BARGAINING POWER OF BUYERS 31 5.1.5 INTENSITY OF RIVALRY 31 5.2 VALUE CHAIN ANALYSIS 32 5.2.1 INPUTS 32 5.2.2 SOFTWARE DEVELOPMENT PROCESSES 33 5.2.3 OUTPUT 33 5.2.4 MARKETING AND DISTRIBUTION 33 5.2.5 POST-SALES MONITORING 33 5.3 IMPACT OF COVID 19 ON EPHARMACY MARKET 34 5.3.3 IMPACT ON COST OF PRODUCT/SOFTWARE 35 5.3.1 IMPACT ON ADOPTION OF SOFTWARE 34 5.3.2 IMPACT ON ADOPTION OF CLOUD-BASED TECHNOLOGIES 35 6 GLOBAL EPHARMACY MARKET, BY DRUG TYPE 6.1 OVERVIEW 37 6.2 PRESCRIPTION DRUGS 39 6.3 OVER THE COUNTER (OTC) DRUGS 40 7 GLOBAL EPHARMACY MARKET, BY OPERATING PLATFORM 7.1 OVERVIEW 48 7.2 APP 50 7.3 WEBSITE 50 8 GLOBAL EPHARMACY MARKET, BY BUSINESS MODEL 8.1 OVERVIEW 52 8.2 MARKETPLACE 54 8.3 PHARMACY 55 8.4 DIRECT 56 9 GLOBAL EPHARMACY MARKET, BY REGION 9.1 OVERVIEW 58 9.2 AMERICAS 60 9.2.1 NORTH AMERICA 62 9.2.1.1 US 65 9.2.1.2 CANADA 67 9.2.2 LATIN AMERICA 69 9.3 EUROPE 71 9.3.1 WESTERN EUROPE 74 9.3.1.1 GERMANY 76 9.3.1.2 FRANCE 78 9.3.1.3 UK 79 9.3.1.4 ITALY 81 9.3.1.5 SPAIN 82 9.3.1.6 REST OF WESTERN EUROPE 84 9.3.2 EASTERN EUROPE 86 9.4 ASIA-PACIFIC 88 9.4.1 CHINA 91 9.4.2 JAPAN 92 9.4.3 INDIA 94 9.4.4 AUSTRALIA 95 9.4.5 SOUTH KOREA 97 9.4.6 REST OF ASIA-PACIFIC 98 9.5 MIDDLE EAST AND AFRICA 100 9.5.1 MIDDLE EAST 102 9.5.2 AFRICA 104 10 COMPETITIVE LANDSCAPE 10.1 OVERVIEW 106 10.2 COMPETITIVE BENCHMARKING 107 10.3 COMPETITOR DASHBOARD 108 10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL EPHARMACY MARKET 109 10.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL EPHARMACY MARKET 110 10.6 KEY DEVELOPMENT ANALYSIS 110 10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 111 10.7.1 ACQUISITION ACTIVITIES 111 10.7.2 NEW PRODUCTS/SERVICE LAUNCHES 112 10.7.3 COLLABORATIONS 113 10.7.4 PARTNERSHIPS 113 10.7.5 APPROVALS 113 11 COMPANY PROFILES 11.1 WALGREENS BOOTS ALLIANCE, INC.. 114 11.1.1 COMPANY OVERVIEW 114 11.1.2 FINANCIAL OVERVIEW 115 11.1.3 PRODUCTS/SERVICES OFFERED 116 11.1.4 KEY DEVELOPMENTS 117 11.1.5 SWOT ANALYSIS 118 11.1.6 KEY STRATEGIES 118 11.2 WAL-MART, INC. 119 11.2.1 COMPANY OVERVIEW 119 11.2.2 FINANCIAL OVERVIEW 119 11.2.3 PRODUCTS/SERVICES OFFERED 120 11.2.4 KEY DEVELOPMENTS 120 11.2.5 SWOT ANALYSIS 121 11.2.6 KEY STRATEGIES 121 11.3 CVS HEALTH... 122 11.3.1 COMPANY OVERVIEW 122 11.3.2 FINANCIAL OVERVIEW 123 11.3.3 PRODUCTS/SERVICES OFFERED 123 11.3.4 KEY DEVELOPMENTS 124 11.3.5 SWOT ANALYSIS 125 11.3.6 KEY STRATEGIES 125 11.4 DR. FOX PHARMACY 126 11.4.1 COMPANY OVERVIEW 126 11.4.2 FINANCIAL OVERVIEW 126 11.4.3 PRODUCTS/SERVICES OFFERED 127 11.4.4 KEY DEVELOPMENTS 127 11.4.5 SWOT ANALYSIS 128 11.4.6 KEY STRATEGIES 128 11.5 DOCMORRIS N.V. 129 11.5.1 COMPANY OVERVIEW 129 11.5.2 FINANCIAL OVERVIEW 129 11.5.3 PRODUCTS/SERVICES OFFERED 130 11.5.4 KEY DEVELOPMENTS 131 11.5.5 SWOT ANALYSIS 131 11.5.6 KEY STRATEGIES 131 11.6 ROWLANDS PHARMACY.. 132 11.6.1 COMPANY OVERVIEW 132 11.6.2 FINANCIAL OVERVIEW 132 11.6.3 PRODUCTS/SERVICES OFFERED 133 11.6.4 KEY DEVELOPMENTS 133 11.6.5 SWOT ANALYSIS 133 11.6.6 KEY STRATEGIES 134 11.7 OPTUMRX. 135 11.7.1 COMPANY OVERVIEW 135 11.7.2 FINANCIAL OVERVIEW 135 11.7.3 PRODUCTS/SERVICES OFFERED 136 11.7.4 KEY DEVELOPMENTS 136 11.7.5 SWOT ANALYSIS 137 11.7.6 KEY STRATEGIES 137 11.8 THE ONLINE DRUGSTORE. 138 11.8.1 COMPANY OVERVIEW 138 11.8.2 FINANCIAL OVERVIEW 138 11.8.3 PRODUCTS/SERVICES OFFERED 139 11.8.4 KEY DEVELOPMENTS 139 11.8.5 SWOT ANALYSIS 140 11.8.6 KEY STRATEGIES 140 11.9 WELL PHARMACY 141 11.9.1 COMPANY OVERVIEW 141 11.9.2 FINANCIAL OVERVIEW 141 11.9.3 KEY DEVELOPMENTS 142 11.9.4 SWOT ANALYSIS 143 11.9.5 KEY STRATEGIES 143 11.10 LLOYDSPHARMACY 144 11.10.1 COMPANY OVERVIEW 144 11.10.2 FINANCIAL OVERVIEW 145 11.10.3 PRODUCTS/SERVICES OFFERED 146 11.10.4 KEY DEVELOPMENTS 146 11.10.5 SWOT ANALYSIS 146 11.10.6 KEY STRATEGIES 147 12 APPENDIX 12.1 REFERENCES 148 12.2 RELATED REPORTS 148

LIST OF TABLES TABLE 1 LIST OF ASSUMPTIONS 17 TABLE 2 GLOBAL EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 39 TABLE 3 GLOBAL EPHARMACY MARKET, FOR PRESCRIPTION DRUGS, BY REGION, 2017–2027 (USD MILLION) 40 TABLE 4 GLOBAL EPHARMACY MARKET, FOR OVER THE COUNTER (OTC) DRUGS, BY REGION, 2017–2027 (USD MILLION) 40 TABLE 5 GLOBAL EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 49 TABLE 6 GLOBAL EPHARMACY MARKET, FOR APP, BY REGION, 2017–2027 (USD MILLION) 50 TABLE 7 GLOBAL EPHARMACY MARKET, FOR WEBSITE, BY REGION, 2017–2027 (USD MILLION) 51 TABLE 8 GLOBAL EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 9 GLOBAL EPHARMACY MARKET, FOR MARKETPLACE, BY REGION, 2017–2027 (USD MILLION) 50 TABLE 10 GLOBAL EPHARMACY MARKET, FOR PHARMACY, BY REGION, 2017–2027 (USD MILLION) 51 TABLE 11 GLOBAL EPHARMACY MARKET, FOR DIRECT, BY REGION, 2017–2027 (USD MILLION) 51 TABLE 12 GLOBAL EPHARMACY MARKET, BY REGION, 2017–2027 (USD MILLION) 59 TABLE 13 AMERICAS: EPHARMACY MARKET, BY REGION, 2017–2027 (USD MILLION) 60 TABLE 14 AMERICAS: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 61 TABLE 15 AMERICAS: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 61 TABLE 16 AMERICAS: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 17 NORTH AMERICA: EPHARMACY MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 63 TABLE 18 NORTH AMERICA: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 63 TABLE 19 NORTH AMERICA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 64 TABLE 20 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 21 US: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 65 TABLE 22 US: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 66 TABLE 23 US: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 24 CANADA: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 67 TABLE 25 CANADA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 68 TABLE 26 CANADA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 27 LATIN AMERICA: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 69 TABLE 28 LATIN AMERICA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 69 TABLE 29 LATIN AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 30 EUROPE: EPHARMACY MARKET, BY REGION, 2017–2027 (USD MILLION) 71 TABLE 31 EUROPE: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 72 TABLE 32 EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 73 TABLE 33 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 34 WESTERN EUROPE: EPHARMACY MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 74 TABLE 35 WESTERN EUROPE: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 75 TABLE 36 WESTERN EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 75 TABLE 37 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 38 GERMANY: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 76 TABLE 39 GERMANY: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 77 TABLE 40 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 41 FRANCE: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 78 TABLE 42 FRANCE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 78 TABLE 43 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 44 UK: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 79 TABLE 45 UK: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 80 TABLE 46 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 47 ITALY: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 81 TABLE 48 ITALY: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 81 TABLE49 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 50 SPAIN: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 82 TABLE 51 SPAIN: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 83 TABLE 52 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 53 REST OF WESTERN EUROPE: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 84 TABLE 54 REST OF WESTERN EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 85 TABLE 55 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 56 EASTERN EUROPE: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 86 TABLE 57 EASTERN EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 86 TABLE 58 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 59 ASIA-PACIFIC: EPHARMACY MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 88 TABLE 60 ASIA-PACIFIC: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 89 TABLE 61 ASIA-PACIFIC: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 90 TABLE 62 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 63 CHINA: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 91 TABLE 64 CHINA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 91 TABLE 65 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 66 JAPAN: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 92 TABLE 67 JAPAN: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 93 TABLE 68 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 69 INDIA: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 94 TABLE 70 INDIA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 94 TABLE 71 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 72 AUSTRALIA: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 95 TABLE 73 AUSTRALIA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 96 TABLE 74 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 75 SOUTH KOREA: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 97 TABLE 76 SOUTH KOREA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 97 TABLE 77 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 78 REST OF ASIA-PACIFIC: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 98 TABLE 79 REST OF ASIA-PACIFIC: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 99 TABLE 80 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 81 MIDDLE EAST AND AFRICA: EPHARMACY MARKET, BY REGION, 2017–2027 (USD MILLION) 100 TABLE 82 MIDDLE EAST AND AFRICA: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 101 TABLE 83 MIDDLE EAST AND AFRICA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 101 TABLE 84 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 85 MIDDLE EAST: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 102 TABLE 86 MIDDLE EAST: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 103 TABLE 87 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 88 AFRICA: EPHARMACY MARKET, BY DRUG TYPE, 2017–2027 (USD MILLION) 104 TABLE 89 AFRICA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2017–2027 (USD MILLION) 104 TABLE 90 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2017–2027 (USD MILLION) 49 TABLE 91 MAJOR MANUFACTURERS IN THE GLOBAL EPHARMACY MARKET 106 TABLE 92 BENCHMARKING OF MAJOR COMPETITORS 107 TABLE 93 COMPETITOR DASHBOARD: GLOBAL EPHARMACY MARKET 108 TABLE 94 MOST ACTIVE PLAYER IN THE GLOBAL EPHARMACY MARKET 110 TABLE 95 ACQUISITION ACTIVITIES 111 TABLE 96 NEW PRODUCTS/SERVICE LAUNCHES 112 TABLE 97 COLLABORATIONS 113 TABLE 98 PARTNERSHIPS 113 TABLE 99 APPROVALS 113 TABLE 100 WALGREENS BOOTS ALLIANCE, INC.: PRODUCTS/SERVICES OFFERED 116 TABLE 101 WALGREENS BOOTS ALLIANCE, INC.: KEY DEVELOPMENTS 117 TABLE 102 WAL-MART, INC.: PRODUCTS/SERVICES OFFERED 120 TABLE 103 WAL-MART, INC.: KEY DEVELOPMENTS 120 TABLE 104 CVS HEALTH: PRODUCTS/SERVICES OFFERED 123 TABLE 105 CVS HEALTH: KEY DEVELOPMENTS 124 TABLE 106 DR. FOX PHARMACY: PRODUCTS/SERVICES OFFERED 127 TABLE 107 DR. FOX PHARMACY: KEY DEVELOPMENTS 127 TABLE 108 DOCMORRIS N.V.: PRODUCTS/SERVICES OFFERED 130 TABLE 109 DOCMORRIS N.V.: KEY DEVELOPMENTS 131 TABLE 110 ROWLANDS PHARMACY: PRODUCTS/SERVICES OFFERED 133 TABLE 111 OPTUMRX: PRODUCTS/SERVICES OFFERED 136 TABLE 112 OPTUMRX: KEY DEVELOPMENTS 136 TABLE 113 THE ONLINE DRUGSTORE: PRODUCTS/SERVICES OFFERED 139

3M, B. Braun Melsungen AG, Baxter International INC, Smith & Nephew Plc, Cardinal Health, Coloplast Corp., ConvaTec Group Plc, Integra Lifesciences Holdings Corporation, Mölnlycke Health Care AB, and Avery Dennison Corporation